Scleroderma

FDA Approves Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease

The Food and Drug Administration (FDA) has approved Ofev (nintedanib; Boehringer Ingelheim) capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Specific Factors Identify Patients at Risk for Disease Progression in SSc Clinical Trials

Researchers identified predictive factors associated with mortality and worsening of organ function in diffuse systemic sclerosis.

Skin Improvement Parallels Early Diffuse Cutaneous SSc Improvement

Disease improvement parallels skin improvement in early dcSSc — this is important for prognosis, and reflects the value of mRSS as an outcome measure in trials.

Abatacept Well-Tolerated But Has Minimal Benefit in Diffuse Cutaneous Systemic Sclerosis

Researchers assessed the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?

Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.

Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?

Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.

SSc-PAH Risk Category Improves With Ambrisentan and Tadalafil Combination Therapy

Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.

Red Cell Distribution Width May Be a Biomarker for Early Pulmonary Hypertension in SSc

Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.

Progressive Skin Fibrosis in SSc Associated With Lung Function Decline

In patients with diffuse cutaneous systemic sclerosis, developing progressive skin fibrosis within 1 year is associated with a decline in lung function and worse survival.

Rituximab Safe, Effective in Patients With Systemic Sclerosis

Rituximab treatment improved skin fibrosis in a cohort of patients with SSc, but no significant change was observed in lung fibrosis.